Publications

Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert opinion on therapeutic targets. 2004. PMID: 15268628


John Park, MD

Logan AC, Haas DL, Kafri T, Kohn DB. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. Journal of virology. 2004. PMID: 15280451


Aaron Logan, MD, PhD

Naing A, Messina JL, Vrionis FR, Daud AI. Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. PMID: 15284274


Adil Daud, MD

Gudmundsdottir K, Ashworth A. BRCA2 in meiosis: turning over a new leaf. Trends in cell biology. 2004. PMID: 15308204


Alan Ashworth, PhD

Halabi S, Small EJ, Vogelzang NJ, Barrier RC, George SL, Gilligan TD. Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology. 2004. PMID: 15302462


Eric Small, MD

Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ, Komanduri KV. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood. 2004. PMID: 15284108


Krishna Komanduri, MD

Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, N.Y.). 2004. PMID: 15256671


Neil Pravin Shah, MD

J. L. Rubenstein, A. Shen, L. Abrey, D. Combs, C. Haqq, L. Damon, J. O'Brien, P. O'Connor, M. Prados, M. Shuman. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 2004. PMID:


James Rubenstein, MD, PhD

J. L. Rubenstein, A. Shen, L. Abrey, D. Combs, C. Haqq, L. Damon, J. O'Brien, P. O'Connor, M. Prados, M. Shuman. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 2004. PMID:


James Rubenstein, MD, PhD

Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer. 2004. PMID: 15221993


Eric Small, MD

Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer. 2004. PMID: 15221993


John Park, MD

Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. PMID: 15217939


Mark Moasser, MD

Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochimica et biophysica acta. 2004. PMID: 15172699


Alan Ashworth, PhD

Mizenina OA, Moasser MM. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell cycle (Georgetown, Tex.). 2004. PMID: 15136770


Mark Moasser, MD

Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine. 2004. PMID: 15149785


Jay Levy, MD

Small EJ. Monoclonal antibody therapy for prostate cancer: finally a reality? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. PMID: 15173211


Eric Small, MD

Rini BI, Weinberg V, Small EJ. Practice and progress in kidney cancer: methodology for novel drug development. The Journal of urology. 2004. PMID: 15126769


Eric Small, MD

Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. PMID: 15173097


John Park, MD

Dhaliwal G, Cornett PA, Tierney LM. Hemolytic anemia. American family physician. 2004. PMID: 15202694


Patricia Cornett, MD

Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. PMID: 15173098


John Park, MD